Omicia Introduces Opal Clinical, Interpretation Software for NGS Diagnostics
OAKLAND, Calif.–(BUSINESS WIRE)–Omicia, Inc., the leading genome interpretation company, today announced the commercial availability of Opal ClinicalTM, the company’s software solution for diagnostic testing organizations. With the cost of next-generation sequencing rapidly decreasing, the time and effort required for interpretation is becoming the rate-limiting factor to making genomics a reality in the clinic. Opal Clinical is a comprehensive solution that addresses this bottleneck. With Opal Clinical, hospitals and diagnostic labs can launch NGS tests faster and interpret results more accurately and quickly.
“We introduce Opal Clinical as genomics expands beyond the research lab into the clinic,” said Mike Aicher, CEO at Omicia. “Opal Clinical meets today’s stringent requirements for clinical bioinformatics solutions — accuracy, scalability, quick turnaround and repeatability. With Opal Clinical, diagnostic labs have a robust platform to interpret genomic tests and generate clinical reports that help diagnose disease and inform treatment plans. Every step leads us closer to personalized medicine.”
A scalable Software-as-a-Service (SaaS) solution, Opal Clinical was built for the new generation of genomic diagnostic tests. Omicia’s comprehensive approach, including unique algorithms for interpreting vast amounts of NGS data, increases the accuracy and reduces the cost of interpretation.
Omicia’s Opal Clinical key features include:
- Support for targeted gene panels as well as whole exome or genome tests
- Complete clinical interpretation workflow to speed turnaround time while ensuring comprehensiveness
- Generation of lab-branded physician-ready clinical reports, as well as APIs for integration with LIMS and EHRs
- Comprehensive variant curation within panels to accelerate patient interpretation
- HIPAA and CLIA compliance
“To realize the potential of using NGS in the clinic, we need new methods and approaches to genomic data,” said Heidi Rehm, Ph.D, Chief Laboratory Director at Partners’ Laboratory for Molecular Medicine and Associate Professor of Pathology at Brigham & Women’s Hospital and Harvard Medical School. “Omicia’s long history in genomic research and leadership role in clinical bioinformatics brings a powerful approach for genome interpretation harnessing leading-edge technology, and advanced algorithms so clinical labs can accurately diagnose disease. The new Clinical Opal product is a terrific platform for bringing together DNA sequence and classic genetics knowledge, and allows interdisciplinary teams of molecular biologists, geneticists, and genetic counselors to rapidly produce clinician-ready reports.”
“We are excited to partner with Omicia on its clinical application,” said Sean Hofherr, Director of Molecular Diagnostics at Children’s National. “Opal Clinical will enable us to support our NGS testing for rare disease diagnosis. As genomics enters the clinic, there is a critical need for robust solutions that meet the quality and turnaround time requirements of pediatric genomic centers like ours.”
“Opal Clinical builds on the success of Omicia’s industry-leading research product, Opal, which has been validated on thousands of genomes,” said Charlene Son Rigby, Vice President, Products, at Omicia. “Opal Clinical integrates the Opal annotation platform, standardized interpretation workflows and full support for clinical report generation – all seamlessly integrated into a diagnostic organization’s lab workflow.”
Hospital and clinical lab customers can tap Omicia Clinical Services and its Expert Network to more quickly launch genomic tests, and provide additional resources for clinical interpretation.
Availability
Opal Clinical is available immediately.
For more information please visit http://www.omicia.com.
About Omicia, Inc.
Omicia delivers genome analysis solutions for research, diagnostic and clinical applications. Our market-leading software platform enables analysis, interpretation and reporting on genomic data to expedite diagnosis and improve medical outcomes. Omicia’s products are in use at more than 300 world-class academic and clinical institutions worldwide. By accelerating understanding of the genetic basis of disease, drug response and health, Omicia is unlocking the potential of individualized medicine. Headquartered in Oakland, California, Omicia was founded by renowned industry veterans with a deep understanding of technology, genomics and diagnostics. Investors include Artis Ventures, Acadia Woods, Bay City Capital, Buchanan Investments, Casdin Capital and Yuri Milner. For more information, visit www.omicia.com and follow us on Twitter @omicia.
